Skip to main content
. 2024 Aug 8;16(16):2792. doi: 10.3390/cancers16162792

Figure 8.

Figure 8

Effect on GT-in-DcNP treatment on human breast cancer MDA-231-HM orthotopic mouse model. Athymic mouse inoculated with 2 million luciferase-transfected MDA-231-HM human breast cancer cells. These mice were then treated with a placebo (control) or GT-in-DcNP (test treatment product) by subcutaneous injection on days 1, 7, 14, and 21. The G:T dose given was 20:2 mg/kg on day 1 and 10:1 mg/kg on days 7, 14, and 21. The effects of GT-in-DcNP or placebo treatment were presented as two-panels. These data present the bioluminescence intensity starting on day 4 to monitor MDA-231-HM tumor growth at the axillary (Panel (A)) and the sub-iliac (Panel (B)) locations. DcNP treatment effects on tumor weights were compared to placebo treatments for MDA-231-HM tumors isolated from the axillary (Panel (C)) and sub-iliac (Panel (D)) sites on day 28. * p < 0.05, *** p < 0.001 based on Student’s t-test. Panel (E) presents bioluminescence images of MDA-231-HM tumors from saline control and GT-in-DcNP groups on day 28.